Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIQ vs AEROSEB-DEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Ophthalmic corticosteroid-responsive inflammatory conditions with concurrent bacterial infection or risk of infection,Blepharitis,Conjunctivitis,Keratitis,Iritis,Cyclitis
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
2 puffs (100 mcg each) intranasally twice daily
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Dexamethasone is metabolized primarily in the liver via CYP3A4; topical antibiotics (neomycin, polymyxin B) are minimally absorbed and not significantly metabolized.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Vd is 3-4 L/kg, indicating extensive tissue distribution with accumulation in liver and kidneys.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Oral: 40-50% due to first-pass metabolism; Topical: 5-10% systemically; IV: 100%.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No adjustment required for any GFR level
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Child-Pugh Class A: no adjustment; Child-Pugh Class B/C: no data available; use with caution
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Children 6-11 years: 1 puff (50 mcg) per nostril twice daily; Children ≥12 years: same as adult
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No specific dose adjustment; monitor for adrenal suppression and osteoporosis risk with prolonged use
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Prolonged use may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Prolonged use may lead to ocular hypertension/glaucoma,Posterior subcapsular cataract formation,Delayed wound healing,Secondary ocular infections (including fungal infections),Corneal/scleral thinning and perforation,Systemic absorption with prolonged use (especially in children),Avoid use in patients with known hypersensitivity to any component
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Epithelial herpes simplex keratitis (dendritic keratitis),Vaccinia, varicella, and other viral infections of the cornea and conjunctiva,Mycobacterial infections of the eye,Fungal diseases of ocular structures,Hypersensitivity to any component of the formulation
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
No specific food interactions. Avoid grapefruit juice as it may increase systemic exposure to ciclesonide via CYP3A4 inhibition.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Pregnancy Category C. First trimester: potential for teratogenicity based on animal studies; avoid unless benefit outweighs risk. Second/third trimester: drug may cause fetal harm due to pharmacological effects; use only if clearly needed.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Excreted in human milk in unknown amounts; M/P ratio not established. Caution advised due to potential for serious adverse reactions in nursing infants; discontinue drug or nursing depending on importance to mother.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
No established dose adjustments in pregnancy; pharmacokinetics may be altered due to increased plasma volume and metabolism. Use lowest effective dose; individualize therapy based on clinical response.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
AEROSEB-DEX is a fixed-dose combination of an inhaled corticosteroid (ciclesonide) and a long-acting beta-agonist (formoterol). Use as maintenance therapy for asthma, not for acute bronchospasm. Rinse mouth after inhalation to prevent oral candidiasis. Monitor for adrenal suppression with prolonged use. Dose formoterol component at low to moderate doses to minimize risk of asthma-related death.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
Use regularly as prescribed, not for sudden breathing problems.,Rinse mouth with water after each use to prevent thrush.,Do not stop suddenly; taper under doctor guidance.,Seek emergency if rescue inhaler not effective.,Report worsening asthma, chest pain, or signs of steroid excess.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIQ vs AEROSEB-DEX, answered by our medical review team.
ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. AEROSEB-DEX is a Topical Corticosteroid that works by The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIQ and AEROSEB-DEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. The standard adult dose of AEROSEB-DEX is: 2 puffs (100 mcg each) intranasally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIQ and AEROSEB-DEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. AEROSEB-DEX is classified as Category C. Pregnancy Category C. First trimester: potential for teratogenicity based on animal studies; avoid unless benefit outweighs risk. Second/third trimester: drug may cause fetal harm . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.